You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
翰森製藥(03692.HK):重獲阿美替尼在中國境外的研究、開發、生產和商業化權益

格隆匯8月4日丨翰森製藥(03692.HK)發佈公吿,集團收到EQRx, Inc.(“EQRx”)關於終止其與集團附屬公司翰森(上海)健康科技有限公司及江蘇豪森藥業集團有限公司(“附屬公司”)於2020年7月23日訂立的有關阿美替尼的戰略合作和許可協議(“許可協議”)的書面通知,許可協議將於協議約定的期限到期後終止。許可協議終止後,集團將重獲阿美替尼在中國境外的研究、開發、生產和商業化權益。許可協議終止將不會影響集團先前從EQRx獲得的首付款與里程碑付款。雙方後續將討論確定相應過渡安排。

阿美替尼用於一線治療具有EGFR敏感突變的局部晚期或轉移性非小細胞肺癌(“NSCLC”)成人患者及用於治療存在EGFR T790M突變陽性的局部晚期或轉移性 NSCLC成人患者的上市許可申請(“上市許可申請”)正在英國藥品和醫療保健用品管理局(“MHRA”)及歐洲藥品管理局(“EMA”)審評過程中。過渡完成後,集團將負責推進MHRA和EMA對阿美替尼上市許可申請審評的監管程序。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account